Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 7710 results

  1. Ranibizumab port delivery system for treating diabetic macular oedema ID6137

    Awaiting development [GID-TA11065] Expected publication date: TBC

  2. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: 21 May 2025

  3. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

  4. KardiaMobile for detecting atrial fibrillation (MTG64)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  5. GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  6. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

  7. Curos for preventing infections when using needleless connectors (MTG44)

    Evidence-based recommendations on Curos for preventing infections when using needleless connectors.

  8. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

  9. XprESS multi sinus dilation system for treating chronic sinusitis (MTG30)

    Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed.

  10. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

      Status ...

  11. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040

    Awaiting development [GID-TA11591] Expected publication date: TBC

  12. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

    Awaiting development [GID-TA11594] Expected publication date: TBC

  13. Eszopiclone for treating insomnia TS ID 12020

      Status ...

  14. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

    Awaiting development [GID-TA11596] Expected publication date: TBC

  15. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development [GID-IPG10409] Expected publication date: TBC